Rasmus Holm-Jorgensen
Financieel Directeur/CFO bij ACRIVON THERAPEUTICS, INC.
Vermogen: 210 432 $ op 31-05-2024
Profiel
Rasmus Holm-Jorgensen founded Kiniksa Pharmaceuticals Ltd.
in 2015, where he worked as Chief Strategy & Portfolio Officer from 2015 to 2022.
Mr. Holm-Jorgensen also currently works at Acrivon Therapeutics, Inc., as Chief Financial Officer from 2022.
Mr. Holm-Jorgensen also formerly worked at Synageva BioPharma Corp., as Group Vice President & General Manager from 2011 to 2015.
Mr. Holm-Jorgensen received his graduate degree from the University of Copenhagen.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 14-05-2024 | 27 258 ( 0.09% ) | 210 432 $ | 31-05-2024 |
Actieve functies van Rasmus Holm-Jorgensen
| Bedrijven | Functie | Begin |
|---|---|---|
| ACRIVON THERAPEUTICS, INC. | Financieel Directeur/CFO | 01-04-2022 |
Eerdere bekende functies van Rasmus Holm-Jorgensen
| Bedrijven | Functie | Einde |
|---|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Oprichter | 01-04-2022 |
| SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | 01-01-2015 |
Opleiding van Rasmus Holm-Jorgensen
| University of Copenhagen | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| ACRIVON THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
